Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654383 | 1.00 | GCK (0.50) | GCKRARARARBRARGCA12 | |
| SCHEMBL320840 | 0.98 | GCK (0.49) | GCKRARARARBRARGCA12 | |
| Tert-Butylamine SCHEMBL327441 | 0.94 | GCK (0.47) | GCKRARARARBRARG | |
| SCHEMBL1107734 | 0.91 | GCK (0.57) | GCKRARARARBRARG | |
| SCHEMBL2088534 | 0.87 | CA12 (0.54) | GCKRARARARBRARGCA12 | |
| SCHEMBL2668926 | 0.87 | GCK (0.41) | GCKRARARARBRARG | |
| SCHEMBL320646 | 0.87 | CA12 (0.54) | GCKRARARARBRARGCA12 | |
| SCHEMBL1426494 | 0.87 | CA12 (0.54) | GCKRARARARBRARGCA12 | |
| SCHEMBL1107706 | 0.86 | GCK (0.63) | GCKRARARARBRARG | |
| SCHEMBL1107709 | 0.86 | GCK (0.55) | GCKRARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012007758-A2 | PHARMACEUTICAL FORMULATIONS | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, GK | GCK 1/4885RARA 2484/4885RARB 2886/4885 |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | F12, XDH, REN | GCK 2360/4885RARA 615/4885RARB 805/4885 |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | GCKR, GCK, HK1 | GCK 2/4885RARA 2320/4885RARB 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.